Loading…
SCNX
Scienture Holdings, Inc.
NASDAQ· Healthcare· Pharmaceutical Retailers· CUSIP 80880X104
$0.39+3.68%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $16.18M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.06
- ROE
- -53.47%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 3.96
- 52-week high
- $2.60
- 52-week low
- $0.24
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.6% over 5Y.
today you would have $6.03▼ -99.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.51 | $6.05 | $5.20 | $6.05 | $35.40 | $79.35 | $99.00 | $27.00 | $40.50 | $41.40 | $99.00 | $153.00 | |
| P/E | — | — | 2.4x | — | — | — | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NMTCNEUROONE MEDICAL TECHNOLOGIES Corp | $1.77 | — | 4.1x | — | -124.66% | $16.12M |
| MDCXMedicus Pharma Ltd. | $0.26 | — | — | — | -7446.11% | $16.28M |
| ADVBAdvanced Biomed Inc. | $9.70 | 2.4x | 1.5x | — | 71.33% | $16.03M |
| ADILAdial Pharmaceuticals Inc | $5.60 |
About the company
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
- 4
- Commack, United States
Company description provided by Yahoo Finance.